Physician

Reema Hasan, M.D.

According to 2025 Medicare claims, Reema Hasan, M.D. (NPI: 1801007638) practices advanced heart failure and transplant cardiology in the Detroit-Dearborn-Livonia, MI market, with the plurality of this provider's patient population coming from Wayne, MI. This provider's primary affiliated billing organization is REGENTS OF THE UNIVERSITY OF MICHIGAN (NPI: 1891205969; TIN: 386006309) and primary practice location at 48109-5000. Hasan is affiliated with the POM ACO (ACO ID: A1297) and Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Hasan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 125 traditional Medicare patients, billed 363 HCPCS/CPT codes, and received $33,505 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,839 prescription claims across 177 beneficiaries totaling $582,716 in drug costs, led by Jardiance (Empagliflozin). DME data shows 232 claims. Open Payments data shows 2 records totaling $150. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $67,296 and ending at $33,505. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $44,773 to $582,716. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	217	868	$67,296
2016	213	775	$56,850
2017	222	896	$67,441
2018	110	299	$18,105
2019	201	931	$64,362
2020	148	555	$40,547
2021	130	419	$39,279
2022	159	524	$46,683
2023	135	465	$40,957
2024	125	363	$33,505

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	92	796	$44,773
2016	108	1,211	$69,847
2017	124	1,316	$90,161
2018	112	1,128	$83,367
2019	145	1,424	$162,537
2020	154	1,762	$205,857
2021	136	1,388	$143,133
2022	156	1,680	$209,917
2023	181	1,651	$346,586
2024	177	1,839	$582,716

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	220	$12,613
2016	34	268	$12,191
2017	22	297	$29,806
2018	N/R	220	$19,394
2019	N/R	267	$17,656
2020	N/R	364	$55,507
2021	N/R	241	$28,548
2022	N/R	234	$30,011
2023	N/R	198	$22,494
2024	N/R	232	$14,294

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	14	18	$139
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	96	170	$102
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	31	95	$94
99239	Hospital discharge day management, more than 30 minutes	12	14	$91
93750	Evaluation of lower heart chamber assist device	12	24	$31

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	114	6,498	$120,034
Entresto	Sacubitril/Valsartan	70	5,240	$112,377
Eliquis	Apixaban	71	3,450	$64,546
Farxiga	Dapagliflozin Propanediol	22	1,510	$28,291
Repatha Sureclick	Evolocumab	19	590	$11,144

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7503	Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg	N	N/R	11	$9,051
J7520	Sirolimus, oral, 1 mg	N	N/R	30	$1,805
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	42	$1,281
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	62	$1,279
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	46	$847

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$150	Abbott Laboratories
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Reema Hasan, M.D.?

Tedicare shows public-source Medicare data for Reema Hasan, M.D. (NPI 1801007638), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Reema Hasan, M.D. have ACO affiliation data?

Reema Hasan, M.D. is shown with ACO affiliation data for POM ACO (MSSP, ACO ID A1297) and Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Reema Hasan, M.D.?

Reema Hasan, M.D. is linked to REGENTS OF THE UNIVERSITY OF MICHIGAN (billing NPI 1891205969) in the available physician profile data.

Does Reema Hasan, M.D. have Open Payments data?

Reema Hasan, M.D. has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.